Table 2 Association of baseline variables with stunting, wasting and underweight in 2016

Gender

 Boy

629 (29.2)

1

488 (22.0)

1

606 (28.1)

1

 Girl

430 (23.0)

0.71 (0.61–0.83)

381 (19.8)

0.86 (0.70–1.04)

455 (24.3)

0.89 (0.68–0.94)

Age in months

 3–12

79 (13.5)

1

162 (27.7)

1

132 (22.5)

1

 13–24

262 (30.4)

3.07 (2.26–4.18)

248 (28.8)

1.04 (0.76–1.42)

272 (31.6)

1.72 (1.29–2.28)

 25–36

308 (32.2)

3.38 (2.48–4.54)

174 (18.2)

0.48 (0.35–0.67)

277 (28.9)

1.50 (1.13–1.98)

 37–48

226 (26.9)

2.58 (1.88–3.48)

140 (16.7)

0.41 (0.29–0.58)

195 (23.2)

1.05 (0.79–1.40)

 48 + 

184 (23.6)

2.09 (1.53–2.85)

132 (16.9)

0.44 (0.31–0.63)

185 (23.7)

1.10 (0.82–1.47)

Country

 Burkina Faso

520 (25.2)

1

552 (26.3)

1

631 (30.5)

1

 Mali

539 (27.5)

1.13 (0.97–1.32)

317 (15.6)

0.43 (0.35–0.54)

430 (21.9)

0.58 (0.49–0.70)

Intervention arm

447 (21.6)

 Placebo

547 (27.1)

1

422 (20.4)

1

545 (27.0)

1

 AZ

512 (25.5)

0.91 (0.79–1.07)

0.89 (0.73–1.10)

516 (25.7)

0.92 (0.78–1.09)

Distance to health facility

 < 1 km

341 (26.2)

1

194 (14.4)

1

253 (19.5)

1

 1–4 km

348 (23.5)

0.86 (0.71–1.04)

371 (24.5)

2.24 (1.73–2.90)

426 (28.7)

1.78 (1.44–2.20)

 5–9 km

220 (29.4)

1.18 (0.95–1.47)

191 (24.8)

2.35 (1.72–3.20)

244 (32.6)

2.22 (1.72–2.86)

 10 + km

150 (30.4)

1.25 (0.97–1.61)

113 (22.3)

1.86 (1.31–2.64)

138 (27.9)

1.66 (1.25–2.21)

SP dose (mg/kg)

 < 25

2 (6.9)

0.20 (0.04–0.87)

1 (3.2)753 (18.9)

0.12 (0.01–1.01)

0 (0.0)

Not relevant^a

 25–70

986 (25.5)

1

115 (89.8)

1

934 (24.1)

 > 70

71 (55.9)

4.26 (2.82–6.43)

89.5 (39.7–202)

127 (100.0)

AQ dose (mg/kg)

 < 10

42 (5.5)

0.15 (0.10–0.21)

33 (4.2)

0.18 (0.12–0.26)

1 (0.1)

0.004 (0.001–003)

 10–15

605 (25.7)

1

423 (17.4)

1

506 (21.5)

1

  > 15

412 (45.4)

2.68 (2.20–3.37)

413 (45.3)

5.16 (4.00–6.67)

554 (61.1)

7.05 (5.38–9.25)